IMPORTANCE Strategies to increase access to palliative care, particularly for racial/ethnic minorities, must maximize primary palliative care and community-based models to meet the ever-growing need in a culturally sensitive and congruent manner.
L atinos are more likely to die in an institution, 1 are less likely to receive adequate pain control, 2 and less often receive hospice services than nonminorities. 3 Early patient-centered, specialty palliative care (PC) improves quality of life (QOL), symptom burden, and advance care planning (ACP) for patients with cancer, ensuring that care is congruent with patient goals, values, and preferences. 4, 5 Specialty-level PC (tertiary palliative care) cannot grow fast enough to meet demand 6 ; therefore, primary PC models are required, especially in poor urban and rural settings. 7 Minority patients are consistently underrepresented in PC trials, increasing the gap in quality PC outcomes. 8 Cultural and linguistic barriers also increase PC disparities. Patient navigators (PNs) have reduced health disparities in underserved, vulnerable populations by improving cancer screening, follow-up on abnormal test results, and treatment adherence. 9 Research examining PN interventions to improve PC for patients with advanced cancer is limited. 10 The objective of this study was to investigate if a culturally tailored PN intervention can improve PC outcomes (increased ACP, improved pain management, and greater hospice use) for Latino adults with advanced cancer. The trial was registered at ClinicalTrials.gov (NCT01695382), and the trial protocol is available in Supplement 1.
Methods

Sample
The Apoyo con Cariño (Support With Caring) randomized clinical trial was conducted from July 2012 to March 2016. The setting was clinics across the state of Colorado, including an academic National Cancer Institute-designated cancer center, community cancer clinics (urban and rural), and a safety-net cancer center. Patients were recruited from 3 Colorado urban (academic comprehensive cancer center at University of Colorado Comprehensive Cancer Center, Aurora; community cancer center at Cancer Center of Colorado, St Joseph Hospital, Denver; and safety-net cancer center at Denver Health Medical Center, Denver) and 7 Colorado rural (Alamosa, Aspen, Edwards, Glenwood Springs, Grand Junction, Pueblo, and Rifle) community cancer clinics and screened for eligibility (age ≥18 years, self-identified as Latino, spoke either English or Spanish as the primary language at home, and diagnosed as having stage III/IV cancer) by oncology staff (S.O.-S. and other nonauthors). Exclusion criteria included lack of decisional capacity, referred or enrolled in hospice, incarceration, and pregnancy. Recruitment processes have been previously reported. 11 The Colorado
Multiple Institutional Review Board approved this study, and all participants provided written informed consent.
Group Randomization
Patients were randomized using a 1:1 assignment (control vs intervention) after consent and baseline data collection. Randomization was stratified by site with computer-generated blocks (randomly varying 2-6 per block). Patient navigators were unmasked at group assignment; other team members (S.M.F., D.M.K., S.-J. M., and R.M.F.) remained masked.
All participants (control and intervention) received a culturally tailored packet of written information about ACP, pain management, hospice use, and a study-specific advance directive (AD). 12 Materials were at a fifth-grade reading level and available in English and Spanish, per patient preference. An interdisciplinary, bicultural community advisory panel helped select materials.
10,13
Intervention
Intervention patients received at least 5 home visits from a PN and the educational packet. Patient navigator training and intervention content details are available in the eAppendix and eTable 1 in Supplement 2. Patient navigators completed detailed field notes, including tracking the number of contacts and visit length and content. The research team reviewed field notes to ensure intervention fidelity.
Primary Outcome Measures
Several primary outcomes were addressed. These included ACP (electronic health record [EHR] documentation of Medical Durable Power of Attorney, study-specific AD, or other type of comprehensive AD), pain management (Brief Pain Inventory [BPI] ), and hospice use (measured in all patients who died during the study).
Secondary Outcome Measures
Patients completed a sociodemographic survey, the McGill Quality of Life Questionnaire (MQOL), and the Patient Navigation Process and Outcomes Measure (eTable 2 in Supplement 2). Hospice length of stay and a measure of aggressiveness of care at the end of life (chemotherapy within 14 days of death, no hospice use, or ≤3 days of hospice use before death) were also assessed.
Data Collection
Patient navigators collected baseline measures via in-person survey immediately after consent and before randomization. Masked study personnel (D.M.K.) surveyed patients by telephone interview 3 months after enrollment to complete patient-centered measures. On completion of follow-up surveys, patients were asked if they had PN visits; if so, additional questions about satisfaction were completed. At month 46, EHRs were reviewed for ACP documentation, hospice use,
Key Points
Question What is the effect of a culturally tailored patient navigator intervention on advance care planning, pain management, and hospice use?
Findings In this randomized clinical trial of 223 Latino adults with advanced cancer, the advance directive documentation rate was 73 of 112 with navigator visits and 40 of 111 without navigator visits, a significant difference. There were no differences in pain management and hospice use between groups, with a mean pain rating of 3 of 10 (mild pain) and with hospice use in 98 of 120.
Meaning Bicultural patient navigators may help Latino patients with cancer complete advance care planning; there was no benefit for pain management or hospice use.
and aggressiveness of care at the end of life for patients who died during the course of the study. Study processes and satisfaction with the intervention were measured using the Patient Navigator Process and Outcome Measures Survey. This study used an intent-to-treat design.
Statistical Analysis
To assess randomization effectiveness, both groups were compared on participant-level variables, including age, sex, degree of acculturation (primary language at home), socioeconomic status, and diagnoses. To test the effect of the intervention on process and outcome measures and for baseline comparisons, t tests (or Wilcoxon rank sum tests if the distribution was not normal) were used for continuous measures (age, BPI [pain severity subscale and pain interference subscale] , MQOL, hospice use in days for decedents, etc). χ 2 Tests (or Fisher exact tests if the cell size was <5) were used for dichotomous outcome measures (sex, AD documented in the EHR, hospice use, aggressiveness of care at the end of life, Patient Navigation Process and Outcomes Measure, etc). Satisfaction with the intervention was described using frequencies and proportions. Power calculations, based on a sample size of 186 patients after death and dropout, provided more than 90% power to detect a medium effect size of 0.25 for a 2-sided test comparing 2 means at a type I error rate of .05.
Results
Baseline Participant Characteristics
Overall, 318 patients were referred; 25 were ineligible. Patient navigators obtained consent from 223 Latino adults, resulting in a 78.5% (223 of 284) enrollment rate ( Figure) . Reasons for refusal to participate included not needing additional help, perceived study burden, and aversion to PC. There were no significant differences between groups (Table 1) , with no adjustments of baseline covariates. The average patient had a mean (SD) age of 58.1 (13.6) years, was female, had less than a high school education, reported a low socioeconomic status (with an annual income less than $15 000), and had stage IV cancer. Close to 50% (106 of 223) primarily spoke Spanish. Missing data were negligible for primary outcome variables. 
Intervention Delivery
Pain Management and QOL
Both groups reported mild pain intensity (mean pain rating of 3 on a scale of 0-10). Intervention group patients had a mean (SD) reported change from baseline in the BPI pain severity subscale score (range, 0-10) of 0.1 (2.6) vs 0.2 (2.7) in control group patients (P = .88) ( Table 2) . Scores on the BPI pain interference subscale were also mild (<4 of 10); changes were not significantly different between groups. The secondary outcome of MQOL score was high, and the mean change from baseline did not differ significantly between groups. However, intervention patients had a larger mean (SD) change from baseline on the MQOL physical subscale compared with control patients (1.4 [3.1] vs 0.1 [3.0], P = .004).
Hospice and Health Care Use
Over the study period, 121 patients died. Of these, hospice use was high in both groups: 79.7% (47 of 59) of decedents in the intervention group vs 83.6% (51 of 61) of decedents in the control group enrolled in hospice (P = .58) ( Table 2 ). There were no significant differences between groups in the secondary outcomes of hospice length of stay or aggressiveness of care at the end of life.
Discussion
To our knowledge, Apoyo con Cariño (Support With Caring) is the first randomized clinical trial of a culturally tailored PN This study demonstrated a high enrollment rate using scientifically rigorous methods. While the intervention had a significant effect on increasing ACP documentation, there was no effect on pain management and hospice use. Secondary outcomes demonstrated an improvement in the MQOL physical subscale score but no effect on overall QOL or aggressiveness of care at the end of life. What distinguishes this culturally tailored PN intervention from other PC interventions is that the PNs are not directly providing care. Instead, they are trained laypersons empowering and activating patients to seek improved primary PC from their oncologists. We designed the Apoyo con Cariño (Support With Caring) intervention to use lay navigators to allow for possible future scalability and to foster trust within an underserved population consistent with the original PN model by Freeman et al. 9 This study helps to inform the role of the lay PN in the care of underserved cancer populations and determine which aspects of care may require higher-intensity interventions delivered by nurses or specialty PC providers.
We found low rates of pain in both groups. With mean pain scores in the mild category, it is arguably difficult to further improve mild pain. However, some patients reported more moderate pain levels. The lack of effect of the intervention on pain may be related to the PN skill set; it is possible that an oncology nurse may have substantially influenced pain outcomes. However, a nurse-led intervention with underserved rural patients with cancer did not improve symptom intensity in another study.
14 Also, if baseline pain levels had been higher, the intervention may have had a greater effect on clinical improvement in pain scores.
15
In our overall sample, 81.7% (98 of 120) of the patients enrolled in hospice, well above previously reported national averages of a 40% Hispanic enrollment. 16, 17 The National
Hospice and Palliative Care Organization reports that, over the past decade, 6% to 8% of hospice patients have been Hispanic. 3 However, the US Hispanic population is young, and, accounting for crude death rates among Hispanics, the hospice enrollment rate for Hispanic deaths is 38%. 19 Furthermore, community grassroots efforts have shown that widespread adoption of ACP is possible and effective. 20 Unlike pain management and hospice use, the ACP aspect of this intervention did not require a motivated patient to work with his or her health care provider. The PN directly facilitated a conversation about goals and values and helped the patient complete an AD, which the PN brought to the clinic to ensure that it was properly uploaded into the EHR.
Limitations
Our study had some limitations. We used a patient-level randomization stratified by site; therefore, it is possible that our study design allowed more contamination from the intervention than has been shown in other PC trials. Contamination, if it occurred, may have served to improve care for all patients at the clinic. For this stage of the research, a cluster design was beyond the feasible scope and budget. In addition, we achieved 95.2% (177 of 186) of the target 3-month follow-up sample; therefore, it is possible that there may not have been sufficient power to detect some differences (eg, pain severity and overall QOL). We also did not adjust for multiple primary outcomes.
Conclusions
A culturally tailored PN intervention was highly valued by patients and demonstrated improvement in ACP; however, it had no effect on primary outcomes of pain management and hospice use. Further research is needed to understand the effects and appropriate scope of the PN intervention on a national scale in a cluster design. 
I. Hypotheses and Specific Aims
We hypothesize that this patient navigator intervention, involving patients from urban settings, will improve advance care planning, pain management, and hospice utilization for Latinos with advanced cancer.
Specific Aim 1:
Implement proposed intervention of the 5 palliative care-related patient navigator visits across 3 urban and 7 rural/mountain clinical sites. Specific Aim 2: Evaluate the effect of the intervention through a randomized controlled trial involving 240 participants with Stage III/IV cancer on primary outcome measures: improved palliative care overall, increased advance care planning, improved pain management, and increased hospice utilization.
II. Background and Significance
Palliative care, focusing on assistance with advance care planning, decisionmaking, pain and symptom management, psycho-social support, and navigation, has the potential to improve care quality and reduce medical service utilization.
1,2
Temel and colleagues 3 reported that early palliative care in patients with advanced lung cancer significantly improved quality of life, increased survival, and provided less aggressive care at the end of life. Additionally, The American Society of Clinical Oncology recently published an updated position statement supporting the need for oncologists to initiate difficult conversations with patients regarding prognosis, preferences, and palliative care options earlier in the course of illness. A. Disparities in End-of Life Care: Advance Care Planning: Advance Care planning has been characterized by significant disparities based on ethnicity. While nationwide averages of completed advance directives are low for all groups, Latinos are less likely to have a living will, durable power of attorney, or a Do Not Resuscitate (DNR) order. [5] [6] [7] [8] [9] [10] Furthermore, Latinos are more likely to choose very aggressive care in the face of serious or incurable illness and less likely to acknowledge their terminally ill status. 5, 6 Latinos are less likely to have knowledge of advance directives 6, 11, 12 and are more likely to report that they have not discussed advance care planning with their health care providers. 13 This finding is Expanding evidence suggests that adequate pain assessment and management is not achieved for many persons at the end of life. Kutner and colleagues report that even in the care-oriented culture of hospice, 82% of their patients listed pain as the most bothersome symptom, requiring more intensive pain management during the last weeks of life. 16 Ethnicity is increasingly recognized as being predictive of poor pain assessment and management. [17] [18] [19] [20] The barriers to adequate pain management have been identified at the institution level, due to physician bias, and as a result of cultural beliefs. [21] [22] [23] There is documented variation across ethnic groups in how pain symptoms are reported and how pain is managed. 17 Bernabei and colleagues reported that elderly nursing home minority (Hispanic) cancer patients were more likely than Whites not to have received any analgesia. Cleeland and colleagues 24 demonstrated that 42% of outpatient minority patients (Hispanics and Blacks) with metastatic cancer were three times more likely than patients in other settings to be inadequately medicated. In a follow-up study, 21 they found that 65% of minority patients did not receive guideline-recommended analgesic prescriptions, compared with 50% of non-minority patients. Hispanic patients in particular reported less pain relief and had less adequate analgesia. Hispanics, however, also reported more concerns about taking too much medication, were more worried about medication side effects, and felt they needed more information about pain management.
While the number of Latinos in the US continues to increase, pain treatment disparities of Latinos persist with reasons including: patients' discomfort with communicating in health care settings, patients' limited health literacy, and the lack of cultural understanding by providers. 25 Language and cultural barriers prevent many Latino cancer patients, especially those who are monolingual from obtaining proper pain management and palliative care. 20 Latino patient-level barriers include fears of addiction, language proficiency, low health literacy, prioritizing family above pain control, and a belief in the role of suffering at the end of life. 26, 27 C. Culturally Competent Care: Understanding culture or ethnicity is extremely important for gaining a deeper appreciation of how preferences for end-of-life care and pain are expressed and experienced. Cultural, spiritual, and religious values often influence how end-of-life care and pain management are perceived. Ahles and colleagues 28 suggest that a person's culture influences the pain experience. If clinicians from one culture stereotype or believe broad generalizations about patients from another culture, their beliefs or misconceptions may unintentionally affect patient care outcomes. Additionally, some languages contain many different words to describe pain whereas in other languages, a single term is the norm. If an CF-146, Effective 7/10/11 unpleasant sensation is not termed "pain" in a particular language, it may further complicate its detection and treatment. The linguistic screen that prevents such a sensation from being categorized as pain may also prevent the communication of the sensation to caregivers, short-cutting the option for effective treatment of the unpleasant sensation. Thus, cultural variability and differences in pain perception and response may be influenced by the language available to describe the pain experience. Barriers experienced by Latinos included lack of awareness of hospice, language, insensitivity of care providers, socioeconomic factors related to citizenship, prohibitive cost of care, 31 and a preference for family caregiving networks.
D. Disparities in
32
One observed outcome likely related to the low utilization of hospice services is the higher rates of death in an institutional setting rather than at home for Latinos 33 and the increased use of lifeprolonging drugs and interventions 34, 35 which account for substantially higher costs. Death at home is more likely to be associated with other factors commonly desired including having family present, dying with dignity, 36 not being alone, having one's affairs in order, 
38-41
In the decades that have followed, ACS has shown continued commitment to the patient navigator model of care and has demonstrated that navigators can help reduce health disparities in underserved and vulnerable populations by improving rates of cancer screening, follow up on abnormal diagnostic tests, and adherence to chemotherapy regimens. [42] [43] [44] Navigators have also been involved with cancer survivors to ensure emotional support and proper follow up and surveillance. While there has been interest in and acknowledgement that palliative care is an important part of the training of patient navigators, there have been no previous studies examining the effects of a patient navigation intervention to improve palliative care for cancer patients. 45 This trial, using rigorous scientific methods and including the community from the earliest development, represents a unique opportunity to demonstrate the effectiveness of a patient navigation intervention for palliative care. The long-term CF-146, Effective 7/10/11 vision for this intervention is to incorporate the training and intervention into ongoing patient navigator programs within the state and nationwide. When this is accomplished, the entire continuum of cancer care will benefit from patient navigators, including those in need of palliative or end of life care. Four patientnavigator projects underway in Denver, Colorado focused on cancer care will ultimately complement our proposed patient navigation intervention and provide future opportunities for collaboration: 1) La Clinica Tepayac and Promotoras, a program to increase cancer screening for underserved Latinos 2) Patient Navigation Research Program-an NCI/ACS funded multi-site project to identify underserved patients with abnormal screening tests and through patientnavigation decrease time to definitive diagnosis and cancer treatment 3) ACS navigators 4) Breast CARES Program provides psychosocial support through patient-navigation to Latinas diagnosed with breast cancer from diagnosis through treatment and into survivorship.
III. Preliminary Studies/Progress Report
A. Patient Navigator Intervention to Improve Palliative Care for Seriously Ill Latinos (5 K23 AG028957-02): A Feasibility Study (COMIRB 09-620)
Specific Aim 1:
To develop and pilot-test a cultural navigator, or guia, intervention to improve palliative care for seriously ill older Latinos.
Specific Aim 2:
To conduct a randomized controlled vanguard study of the intervention to determine refusal rates, withdrawals rates, and visit and interview completion rates to ascertain feasibility for fully powered RCT of the patient navigator intervention.
B. Intervention Development and Cultural Tailoring:
To develop and inform the intervention Dr. Fischer conducted a series of focus groups addressing end-of-life care in the Latino community at a local community health clinic. The qualitative results emphasized core Latino values, familia, confianza, espiritulismo, and personalismo. This led to the development of our theoretical model (Figure 1 ). Key informant interviews were conducted with other community navigators, community leaders, and local community health care providers to work to operationalize values into navigator interventions. Dr. Fischer convened a bi-cultural Community Advisory Panel composed of academic experts, community leaders, and community members working in the area of patient navigation who worked together to refine the study materials and the content and structure of the home visits, transforming core values to programmatic messages. CF-146, Effective 7/10/11
Figure 1. Theoretical Model
Pilot testing was completed in June 2010 and enrollment in the RCT of the patient navigator intervention began in July 2010. Final study materials and navigator visit structure received positive review from pilot test participants and ongoing RCT feasibility study participants.
C. Feasibility of the Patient Navigator intervention to Improve Palliative Care for Seriously Ill Latinos
The preliminary results from this feasibility study demonstrate that the patient navigator intervention is a feasible and acceptable intervention for Latinos facing serious illness. The study flow figure demonstrates that the team was able to recruit and enroll patients with a 20% enrollment rate. Of the 32 patients in the intervention arm, only 1 patient asked to withdraw from the study. Intervention participants who have completed the intervention had a mean of 5.2 + 3.1 (SD) visits. The five navigator initiated visits took place over a mean of 5 + 2 (SD) months. The subset of patients with cancer (n = 6) all CF-146, Effective 7/10/11 completed the 5 visits within 2 months. In both control and intervention groups, the rate of 3 month data collection by patient interview is 85%.
The PI has also completed qualitative analysis of the detailed field notes of the patient navigator from the preliminary studies and transcribed interviews with participants who received the navigator intervention. Themes of trust, appreciation, and gratitude demonstrated a high degree of satisfaction with the patient navigator and the intervention. The analysis also described less tangible benefits of a patient navigator many activities of the navigator beyond the scope of the prescribed intervention.
IV. Research Methods A. Outcome Measure(s).
An overview of the outcome measures and their source are listed in Table 1 below. Primary outcome measures for the three main domains are simple objective outcomes related to end-of-life care-palliative care overall, advance care planning, pain management and hospice utilization. Secondary outcome measures include the use of aggressive care at the very end of life, 3 and quality of life.
At 3 months from study enrollment date, the PI or Co-I, who is blinded to randomization assignment, will contact participants to complete outcome measures-the Brief Pain Inventory Long Form, the McGill QOL scale, and the Patient Navigator Process and Outcomes Measure (PNPOM). Three months was chosen for the survey outcomes based on our feasibility study demonstrating that ~ 80% of patients are still alive to complete the survey. Three months is enough time to complete the intervention visits but minimize the number of patients who die before follow up data collection can occur. Upon completion of the follow up patient interview, participants in the control and intervention group will receive a $20 grocery gift card as an incentive and gesture of thanks.
At 6 months from study enrollment, the PI and Co-I (RF) will conduct a chart review to collect outcomes data. If death has occurred, the hospice will be contacted to confirm treatment history and length of stay in hospice. Six months was chosen for the chart review to ensure all participants had at least 6 months to complete an advance directive The last month for recruitment is month 41 therefore, all chart review data collection will be completed by month 47.
At month 46, the patient navigator (PRA) will call all the participants who may still be living and collect hospice utilization data. If the navigator is unable to contact the participant, then the Colorado Department of Public Health will be contacted to search for death records which will confirm date of death if the participant has died and if hospice was or was not involved. Hospices will be contacted to confirm all utilization (exact hospice enrollment date and death date). Month 46 was chosen for hospice utilization assessment to maximize the number of hospice days captured for all participants. We recognize the follow-up period will be variable for CF-146, Effective 7/10/11
participants (e.g. those enrolled in month 38 will have a shorter follow up time than for those enrolled in month 6) but due to the randomization scheme, it should not be biased towards intervention or control group.
At month 58 and 70 the follow up procedure for collecting hospice utilization data will be repeated. Qualitative data from our feasibility would suggest that an earlier exposure to the intervention will continue to have an impact on hospice utilization over time. Variables include the 0-10 global QOL assessment and the 4 individual subscales of the MQOLQ -physical symptoms, psychological, existential, and support. The psychological subscale includes two questions that assess depression (depression, sad) and two questions that assess anxiety (nervous or worried, afraid of the future). 46, 47 BPI: (BPI-LF) is a 32-item self-report instrument that assesses the severity and impact of pain in patients with chronic diseases, e.g. cancer. Available in Spanish, the validity and consistency of this instrument is based on the two-factor structure of pain severity and pain impact on function with Cronbach's alpha ranging from 0.77 to 0.91. The psychometrics of the BPI-LF have been well established with cancer patients. [48] [49] [50] Patient Navigation Process and Outcomes Measure: (PNPOM) will capture the less tangible benefits of a patient navigator and help understand the effects of the many activities of the navigator beyond the scope of the prescribed intervention. The questions incorporate aspects of self-efficacy and patient activation (key concepts that patient navigators help improve). Intervention Delivery Cost: We will estimate the unit cost for the guia visits based on the salary of the guia, time, resources used, and training in order to inform future dissemination. In addition, we will explore approaches to measuring cost effectiveness of the intervention in order to capture cost per successful outcome (e.g., cost per completed AD in the chart, cost per referral to hospice) in the treatment and control groups. These activities are designed to further develop a methodology that can be used in future studies. For this proposed study of comparing a patient navigator intervention to control, additional costs to be incurred by adopting the intervention should be weighed against relative benefits of the intervention. It would be difficult to convert the intervention effects (e.g. for completed AD in the chart, and referral to hospice) into corresponding cost savings in terms of dollars to calculate net gains of the intervention, whereas the intervention costs (development, including training of navigator, meetings, planning, and supervision; and implementation, including participant identification, recruitment and screening, resources used and potential replication in other locations) could be estimated.
B. Study Design and Research Methods
Description of Population to be Enrolled: Participants (n = 240) will be recruited from the following sites: Adults (>18 years of age) who self-identify as Latino and have an advanced cancer. All types of cancer will be included. While we acknowledge that the prognosis and survival vary greatly by type of cancer, by broadly focusing on more advanced disease, most patients will have symptom needs and all may benefit from a palliative approach. We will preferentially enroll Stage IV cancer patients. To ensure the study population has adequate representation of more advanced disease with a poorer prognosis, patients with a Stage III cancer will comprise no more than 20% of the study population at any given period of time.
Specific inclusion Criteria: 1) Self-identify as Latino 1) Stage III/IV cancer 2) Receiving chemotherapy, biotherapy, or radiation therapy for cancer 3) Not incarcerated 4) Participants must be able to provide informed consent and speak either English or Spanish as a primary language CF-146, Effective 7/10/11
Recruitment: At each clinic site we have identified a health care provider (e.g. nurse, clinical trials coordinator) who will be the study's onsite coordinator. If patients meet the eligibility criteria and agree to be contacted (HIPAA A) the onsite coordinator will provide patient contact information to the patient navigator (guia) who will then approach the patients for study enrollment. If patients agree to participate, they must give informed consent in writing. The patients must also agree with the HIPAA language in the consent form. These forms will be provided in English or Spanish. The guia will read and summarize each section of the consent form, assessing comprehension as well as willingness to consent. The consent form includes a description of the purpose of the research, risks and benefits, and contact information for the PI/Co-Is and the human participants' protection committee (IRB).
The PI (SF) and Co-I (RF) will oversee the recruitment and consent process, serve as a liaison with the oncology care teams as necessary, and problem solve barriers to palliative care if the navigators need additional assistance Baseline Assessment: Before randomization, study participants will have an initial assessment completed by the guia, focusing on sociodemographic information and the Brief Pain Inventory Long Form, 48, 51 the McGill Quality of Life (QOL) scale, 47 and the Patient Navigator Process and Outcomes Measure. Sociodemographic information will include contact information, date of birth, measures of ethnicity, primary language, and acculturation, and socioeconomic status (occupation-current or former, average annual income, education, and home ownership). The PI (SF) or Co-I (RF) will review medical records for detailed medical data on cancer diagnosis and treatment, for a list of current medications and dosages, and for the presence (and type, if applicable) of an advance care planning document on the chart.
Randomization:
The statistician (SM) will prepare blocked randomization (random permuted blocks) for assigning participants to intervention or control group within each clinic site, stratified by Stage III or IV, to avoid serious imbalance in the number of subjects between the two groups throughout the study period. The block size also will be randomly varied between 2, 4, and 6 to preserve the randomization scheme. The PI and Co-Is will be blinded to study allocation.
Intervention: After the initial contact for the enrollment and consent process, the guia will schedule the first study visit. The function of the initial visit is to establish trust (confianza) and ensure a more personal approach (personalismo) with the participants. In addition, if family members are present this initial visit will provide more opportunity for the guia to establish a relationship with the participants' families (familia) as well. These core Latino values ground the intervention starting at the most preliminary stage. Visit Content Overview: The guia will arrange to meet the participants at the home or another location if the participant prefers (e.g., chemotherapy infusion unit, CF-146, Effective 7/10/11 primary care provider's or oncologist's office). At the first visit, the guia will provide and review the educational materials that cover the domains (selected by the community advisory panel based on the preliminary studies qualitative work) with the participant and family. Additionally, during that visit, the guia will work with the participant and family to create a plan for subsequent visits based on the participants' and families' needs and acceptance of palliative care. A framework of the target domains and the planned intervention by visit is described in Table 2 . Because participants will be at different points in their illness trajectory and participants and families will vary in their acceptance and readiness to address each of the domains, the guia visits will vary in both the content and activities covered during each visit as well as the number of visits. Nevertheless, all of intervention content will be covered with each participant and family during the course of their study participation. The plan will be customized to the needs of each participant. For example, a visit may include accompanying the patient to their oncology or primary care appointment. The educational materials and the visit scripts are included in attachments. Navigator Initiated Visits: Based on data from our patient navigation feasibility study, we have set a "ceiling dose" of 5 planned guia intervention visits. We found in our feasibility study that further time investments were unlikely to yield improved outcomes.
Patient/Family Initiated Visits: The guia will continue to be available to the participants on a non-urgent basis as needed throughout the time of the award. In keeping with the patient-centered approach that grounds both patient navigation and palliative care, the guias will always be responsive to patient or family needs. There will not be a specified limit to the number of additional patient or family initiated visits. Based on our patient navigation feasibility study to date, where 6 of the 18 patients requested 2-5 additional visits, primarily for facilitating hospice care, we expect that 30% of intervention patients may need the additional assistance of the navigator approximately 3 times. Meeting these requests will thus be feasible within the time constraints of the guia.
Control group:
At the time of enrollment, participants in the control group will be given a packet of the same educational materials that are provided to the intervention group, covering the three domains (advance care planning, pain management, and hospice) in the appropriate language (Spanish or English).
D. Description, Risks, and Justification of Procedures and Data Collection
Tools.
Fidelity to the intervention: All participants will have a study tracking chart (stored in a locked file cabinet in a locked office in a secured office suite in a secured building on campus). Using a standardized electronic form (RedCap), the patient navigator (guia) will record the duration of each visit and who was present CF-146, Effective 7/10/11 at the visit. She will also record how each domain was addressed during the visit. She will also keep detailed field notes of what occurred during the visit and how the participants responded to the discussions and activities. The guia will also track phone calls made to the participant. As each visit will be logged in the tracking chart, an accurate count of the total number of visits per participant will be obtained. Careful tracking of the dose of intervention each participant received will allow for a dose response analysis. If participants refuse visits, the guia will attempt to contact the participant or family members to understand the reason for no longer wishing to continue with the program. The reason for drop out will be recorded in the study tracking chart. The navigator will audio-record 10% of their home visits and the Co-I (RF) and PI will review the tape using a fidelity checklist to evaluate if each domain was addressed and if the core Latino values were utilized in the discussion. This detailed study tracking will allow the team to demonstrate fidelity to the intervention for each participant. This level of documentation has been identified as necessary to provide rigor and increase reproducibility. 43 Audio files will then immediately be permanently destroyed.
Data Collection:
To ensure data integrity, the PI developed a data collection manual with detailed description of each measure, instructions for its accurate collection, and acceptable sources. The study will use REDCap, a secure, HIPAA compliant, web-based application for building and managing online databases and is provided free of charge by the University of Colorado CCTSI. The PI and Co-I (RF) will perform the baseline chart review to obtain data on medical diagnoses, co-morbidity measures for the Charlson Index, and current medications. Chart reviews will include 10% reliability testing by PI and Co-Is.
Source of Materials: Data gathered for this study will come from three primary sources: the research participant or family through interviews with the navigator and the participants' medical records or death records. All quantitative data will be entered into REDCap, a secure, HIPAA compliant, web-based application for building and managing online database. Participants will be assigned a unique identifier code. Field note word documents using the key identifier code (not containing protected health information) will be stored on the University of Colorado firewalled, password protected, virtual private network (VPN) on a server accessible only to study team members.
Potential Risks: There are no foreseeable physical, social, psychological, or legal risks beyond those of participating in health-related research in general.
Protection Against Risks: All efforts will be made to protect confidentiality of research participants and their families. All electronic data will be stored in a password-protected program on a password-protected computer, with encryption software, in a locked office. All written data will be stored in a locked file cabinet in a locked office in a locked office suite in a building that is secured by an electronic entry card during off business hours. It is important to note that all participants are CF-146, Effective 7/10/11 receiving care within an institution and the data collected will not include any information that is not readily available in a patient's chart. There will be no questions that would impose legal risk on a participant that is not also readily available in the patient's medical record. There will be no direct questions regarding a participant's immigration status (whether documented versus undocumented). Therefore, there is no significant risk to participants and the protection against risks is adequate.
Data Safety and Monitoring Plan: As this study involves providing education and facilitating selected aspects of palliative care, few adverse events are anticipated. It is possible that addressing issues related to palliative care may cause increased anxiety. As an added protection, a community advisory panel, academic and community persons involved in the development of the intervention, will continue to meet twice a year. They will review enrollment, withdrawals, and any adverse events. Any other concerns raised by the research participants or their families can be discussed in this forum with the permission of the participant or family. This panel will therefore function as a voice and advocate of the participants and the Latino community in general.
E. Potential Scientific Problems. Several important limitations must be considered. The first is the possibility that the participating sites may have a knowledge deficit regarding palliative care and a lack of actual resources to which to refer patients and families. None of the sites have an outpatient palliative care program.
Additionally, tailored interventions inherently raise concerns of reproducibility and quality control. The individualized approach to each participant/family unit is critical to address variability in acceptance of palliative care and differences along the individual's illness trajectory. Therefore, in lieu of a one size fits all approach, careful tracking and documentation of navigator interventions has been recommended to address these concerns. (24) The PI has taken significant steps to ensure the reproducibility and quality control of the intervention. These are detailed in the Fidelity to the Intervention section.
Another limitation is the potential to lose participants to follow up. If death is expected, immigrant patients may return home to Mexico for their final days. Loss to follow up will be minimized by building a trusting relationship with the guias and working with the participant and family to create a plan for the intervention that will work for them. Additionally, there are outcome measures across the three domains that rely solely on secondary data sources rather than self-report.
Finally, we have also chosen to allow a broad focus to all types of cancer. While we acknowledge that the treatments and survival will vary widely by cancer type, all may have symptom needs that are appropriate for our intervention. Our symptom management centers on pain. We felt this was absolutely key-if pain is uncontrolled it is impossible to address goals and values discussions or any other CF-146, Effective 7/10/11 symptoms. We understand that other symptoms may be present and while the navigator does not have written materials specific to other symptoms, by helping patients become activated and advocate for themselves, other symptoms are likely to improve as well.
F. Data Analysis Plan.
Refusal rates, withdrawals, and missing data: The PI and current patient navigator (PRA) have achieved good consent rates (20%) for enrollment in the feasibility RCT. We expect that refusal rates in the proposed study will be lower because the patient navigator and the study will be introduced by a provider from the clinical site and the clinical oncology providers are supportive and committed to promoting this research whereas the feasibility trial was conducted in the acute care setting. De-identified demographic data (gender, age, cancer diagnosis) will be collected on potential participants who refuse to participate to assess the extent to which study participants differ from study decliners. Participants wishing to withdraw will be asked for continued consent to review their medical records and will remain in the database for analysis as randomized (intent-to-treat analysis). If participants withdraw from the study and do not give consent to perform the medical record review, outcome variables will not be available for those subjects and it will not be possible to do a traditional intent-to-treat analysis. Therefore, the statistician (SM) will do a sensitivity analysis, assuming all possible scenarios, if the participant withdrawal rate is >5% or there is a differential withdrawal from one of the study groups. Multiple steps will be taken to minimize missing data. Appropriate imputations or likelihood inference (based on ignorable missing-data mechanism when data are missing at random) will be used to address any severe missing data problems. Due to the expected high mortality rates (~20% at three months) of the study population, sample size was calculated to ensure adequate power for outcome analysis.
Assess effectiveness of randomization: To assess the effectiveness of the randomization procedure, the two groups will be compared across a broad range of variables including but not limited to age, gender, diagnoses, degree of acculturation (e.g., language spoken in the home, immigration history versus native US citizen), baseline presence of an advance directive, and socioeconomic status. Categorical variables will be compared using chi-square tests (or Fisher's exact tests) and continuous variables will be compared using t-tests (or Wilcoxon tests). If the randomization is not effective and significant differences exist between the two groups, covariate adjustment will be used in the analysis to control for the differences. Analysis of Primary Outcome Measures: The study is designed to demonstrate the effectiveness of a patient navigator intervention compared to control using rigorous scientific methodology (randomized controlled trial). For continuous outcome measures from interview (MQOL and Brief Pain Inventory), improvement from CF-146, Effective 7/10/11 baseline to 3 months will be used as outcome variables and compared between groups using t-tests. The arithmetic mean of the four severity items in BPI can be used as a measure of pain severity. (The arithmetic mean of the seven interference items can be used as a measure of pain interference with functional status. Pearson correlations will be calculated to examine relationships between pain intensities and interference. Multiple linear regression analyses will be used to determine the extent to which the pain intensity rating contributes to pain interference once the other ratings are controlled for.) Hospice utilization in days for the referred to hospice will be compared using t-tests (or Wilcoxon tests if skewed). For the dichotomous outcome measure at 6 months (presence of an Advance Directive in the medical record), chi-square tests will be used to test the intervention effect on the outcome. If significant baseline differences exist between the control and intervention groups, then those variables will be used as covariates in linear regression (for continuous measures, potentially using log transformed hospice days as outcome variable if skewed) or logistic regression (for dichotomous measure). In order to reduce bias from outcome variables not being available at follow-up by participant withdrawal, the variables exhibiting differential withdrawal patterns between intervention and control will be adjusted for using regression.
Secondary Analyses: Selected variables will be tested for mediator and moderator effects. Urban/rural classification of the sites will be included as a main effect and an interaction term with intervention in regression to assess the effectiveness of the intervention in the rural setting compared to the urban. Country of origin, acculturation, and belief about value of palliative care will be similarly tested for effect modification. Trust (confianza) and personal approach (personalismo) with participants, and patient satisfaction with intervention will be tested for potential mediator effects, by first fitting regression with intervention as predictor and then adding mediator as predictor.
Aggressive end of life care will be analyzed using t-tests and linear regression for continuous measures, or chi-square tests and logistic regression for dichotomous measures.
Cost-effectiveness will be assessed using incremental costs-to-effects ratio. When we examine dosage effects of the intervention (i.e. relationships between the number visits and outcomes), we will observe marginal changes in dosage and effects. We expect to see diminishing marginal returns, and we will be able to decide an upper limit of dosage beyond which gains become negligible. Nonlinear effects of number of visits will be assessed by including higher order terms for number of visits as predictors in regression. Models will be calibrated for sensitivity based on cost estimates for intervention components.
Statistical Power: Sample size calculations are based on testing the effectiveness of the intervention for primary outcome variables. A target sample size of 240 (120 CF-146, Effective 7/10/11 patients in each group) will provide ample power to detect statistically and clinically significant differences between the two groups. For improvement from baseline to 3 months in continuous outcome measures from interview, MQOL and BPI, 186 patients after death and drop-out, will provide more than 90% power to detect a medium effect size (f=0.25) for a 2-sided test comparing two means at Type I error rate=0.05.
For the dichotomous outcome at 6 months, completed AD, chart review of 240 patients will provide more than 80% power to detect an 18 percentage point difference from the control group rate of AD in chart at 10% -40% (w=0.18 -0.23, small-to-medium effect sizes) for a test comparing two proportions.
For hospice utilization (days used) outcome, effect size was found to be a mean=23 (SD=36) in control and mean=48 (SD=63) in intervention. We have 88% power to detect this effect size using n=168. Dropping one extreme from each group (91 days in control and 153 days in intervention), hospice utilization mean=9 (SD=14) in control and mean=22 (SD=26) in intervention. We have 98% power to detect this effect size using n=168. The n= 168 sample size target for total number in hospice care assumes that 210 patients will be eligible for hospice over the course of the study and that 80% of eligible patients will use hospice before death. This latter assumption is based on actual Colorado hospice utilization data that is available through Hospice Analytics.
Therefore, we will preferentially enroll persons with stage 4 cancer. We will ensure that there are no more than 20% of patient s with stage 3 disease at any given time in the sample.
The patient navigator intervention is a time and resource intensive intervention and a small effect size is not sufficient to justify the upfront costs and resources to hospitals or payer sources. Therefore, we selected a medium effect size although in fact, we will have power to detect something in between a small and medium effect size.
G. Summarize Knowledge to be Gained. Palliative care is an essential part of cancer care. Palliative Care is a medical specialty that focuses on symptom management, quality of life, and helps patients with life limiting illness match goals and preferences for care. Recent oncology literature suggests that when patients talk about end of life decisions with oncology providers, patient distress improves. Furthermore, cancer patients who die at home, as opposed to the hospital, have better symptom control and family members have less PTSD and complicated bereavement. In a recent NEJM article, Temel, et al showed in a RCT of a palliative care intervention, patients with advanced lung cancer had better quality of life, less depression, and lived longer. (23) The overall goal of our project is to improve palliative care for Latinos with advanced cancer by incorporating a 
